Enjoy Free Shipping on Orders above $220
Lortinib 150 mg tablet is a prescription medication specifically designed to treat Non-Small Cell Lung Cancer (NSCLC) in patients with EGFR mutations.RPG Life Sciences Ltd. manufactures Lortinib, which contains Erlotinib (150 mg), an EGFR inhibitor that blocks Cancer cell proliferation, slows tumor progression, and enhances treatment outcomes.
This targeted therapy is crucial for managing advanced NSCLC and pancreatic cancer. It disrupts Epidermal Growth Factor Receptor (EGFR) signaling, preventing Cancer cells from multiplying. By interfering with this pathway, the medication helps delay disease advancement and improve patient survival rates, making it a vital option in oncology.
Lortinib tablet is administered orally under medical supervision and requires regular monitoring to evaluate its efficacy and manage potential side effects.
It is commonly prescribed as a first-line treatment for EGFR mutation-positive lung cancer, significantly improving the overall prognosis. It optimizes therapeutic benefits and supports long-term disease control when taken consistently as directed.
Lortinib tablet is a vital therapy for EGFR mutation-positive Non-Small Cell Lung Cancer (NSCLC) and Pancreatic Cancer. It slows Cancer progression and enhances survival outcomes.
Key benefits of Lortinib 150 mg tablet:
Lortinib 150 tablet is a prescription-only medication. Consult your doctor before use. Follow these guidelines:
Lortinib has various strengths and substitutes. Your doctor will determine the appropriate dosage based on your medical condition and response to treatment.
Available strengths include:
| $95.7 / 10 tablets |
Lortinib 150 tablet is generally safe when taken as prescribed, but some individuals may experience mild to moderate side effects, including:
Seek medical attention if side effects persist or worsen.
Liver disease
Patients with liver disease should use Lortinib cautiously. Regular liver function tests are recommended to monitor potential toxicity and adjust dosage.
Kidney impairment
Those with kidney impairment must take this medication under medical supervision. Based on renal function, dosage adjustments may be required.
Pregnant and breastfeeding women
Lortinib 150 is not recommended during pregnancy or breastfeeding. Consult your doctor for alternative treatments to minimize fetal or infant risk.
Avoid
Avoid alcohol and smoking, as they may reduce drug efficacy. Refrain from driving or operating machinery if you experience dizziness or fatigue.
Lortinib tablet blocks Epidermal Growth Factor Receptors (EGFR), preventing Cancer cells from multiplying. It is particularly effective in EGFR mutation-positive NSCLC, helping slow disease progression, shrink tumors, and improve survival rates, making it a crucial component of targeted therapy.
The effectiveness of the Lortinib tablet varies. Some patients notice symptom relief within 2-4 weeks, while maximum therapeutic benefits typically emerge after 2-3 months. Regular follow-ups help assess progress and make necessary treatment adjustments for optimal outcomes.
No, it should be taken on an empty stomach—at least one hour before or two hours after meals. This ensures proper absorption, enhances drug efficacy, and prevents food interactions that could reduce its effectiveness in targeting cancer cells.
Avoid grapefruit juice, alcohol, and smoking, as they interfere with drug metabolism. Use sunscreen to prevent rashes, drink adequate water to stay hydrated, and attend routine checkups to monitor response and manage any side effects efficiently.
Yes, elderly patients can use the Lortinib tablet, but they require close monitoring due to a higher likelihood of side effects like diarrhea and fatigue. A doctor may adjust the dosage for safer and more effective treatment.
Yes, it is sometimes combined with chemotherapy or radiation therapy to enhance efficacy. Your oncologist will determine the best combination based on your Cancer stage, type, and overall health condition for a comprehensive treatment plan.
